Rarecells

#Cancer isn’t uniform: multiple clones within one tumor drive progression & resistance. While #ctDNA offers a partial snapshot, ISET® isolates intact #CTCs, enabling CTC-DNA analysis that has demonstrated >70% greater detection of tumor heterogeneity vs. ctDNA alone. For more: rarecells.com/technology-new

#ColorectalCancer is the 4th most diagnosed cancer in the US, but deaths have declined since the '80s due to improved screening. Rarecells’ ISET® #LiquidBiopsy platform has been validated in several studies as a non-invasive, repeatable approach to #CancerDetection.. #EnoughCRC rarecells.com/iset-publicati…

In a cross-cancer analysis of 2,800 patients spanning 17 cancer types (Stages II–IV), ISET® has demonstrated 99% average clinical specificity and 91% average clinical sensitivity in detecting circulating tumor cells (#CTCs). High specificity is critical in #LiquidBiopsy to minimize false positives. To read ISET® scientific publications: rarecells.com/iset-publicati…

Yesterday at #BioLabsEuropeanInvestorDay, Rarecells’ CEO Dr. Patrizia Paterlini presented how the company’s work in #LiquidBiopsy is helping to push the boundaries of #EarlyCancerDetection. The Rarecells team was on the ground connecting with partners, investors, and innovators across the biotech community. biolabsinvestorday.com/biolabsinvesto…

Rarecells’ CEO Patrizia Paterlini, MD, Ph.D., will be at #BioLabsEuropeanInvestorDay tomorrow, sharing Rarecells’ vision for advancing earlier and more precise #CancerDetection. We appreciate the opportunity to engage with investors and partners who share our commitment to accelerating innovation in #oncology. biolabsinvestorday.com/biolabsinvesto…

Last month, Rarecells’ CEO, Patrizia Paterlini, MD, Ph.D., and Scientific Advisory Board Member Rita Shaknovich, MD, Ph.D. attended the 2026 Nearness of You Concert at @Jazzdotorg, an inspiring evening dedicated to advancing #cancer research. giving.cuimc.columbia.edu/nearness-you-c…

Founded by our CEO Patrizia Paterlini, MD, Ph.D., Rarecells was built on the goal of making non-invasive #EarlyCancerDetection accessible and accurate. In honor of International Women’s Day yesterday, Rarecells celebrates the women whose curiosity, expertise, and determination are helping shape the future of #oncology. internationalwomensday.com #IWD2026

Circulating tumor cells (#CTCs) have demonstrated significant impact in detection of cancer and its recurrence, understanding tumor DNA, and evaluating treatment options. However, CTC approaches have largely remained within research settings, limited by challenges in sensitivity, speed and scalability. Rarecells’ ISET® technology is designed to overcome these historic challenges with an ultra-sensitive, fast, and scalable solution – ready for molecular and cytological workflows: detecting down to 1 CTC in 10 mL of blood, <10-minute isolation, and stabilized blood up to 72 hours after draw. Learn more: rarecells.com/technology-new #LiquidBiopsy #ctDNA #CancerDiagnostics

Congratulations to Anna Paula Carreta Ruano, Ludmilla T. Domingos Chinen and the hcor team in São Paulo, Brazil for the recent publication highlighting the impact of circulating tumor cells (CTC) and circulating tumor microemboli (CTM) in venous thromboembolism (VTE), a serious complication affecting cancer patients that can be challenging to predict and prevent. The review, published in Bioscience Reports, examines the potential prognostic value of CTCs and CTM – as well as highlighting the advantages of Rarecells’ highly sensitive ISET® technology in capturing these important biomarkers. The study of CTCs and CTMs is highly relevant for personalized prevention and management of VTE - to improve outcomes in the lives of cancer patients. Read the paper: portlandpress.com/bioscirep/arti… #LiquidBiopsy #CTC #Oncology #Thrombosis

Cancer Prevention Awareness Month is a reminder that #EarlyDetection plays a critical role in reducing cancer’s impact. When #cancer is identified sooner, patients have more options for treatment and dramatically improved outcomes. Rarecells joins @AACR in supporting research for #CancerPrevention by advancing #LiquidBiopsy-based diagnostics that support earlier, less invasive detection. Rarecells believes that progress starts with finding cancer before it spreads For more: aacr.org/patients-careg… #EarlyCancerDetection #Oncology #CancerResearch

On #WorldCancerDay, we’re reminded that progress against cancer affects all of us: patients, caregivers, clinicians, researchers, advocates, and communities. @Rarecells supports @worldcancerday’s #UnitedByUnique campaign and reinforces the importance of earlier detection, and more individualized approaches to cancer care. worldcancerday.org/the-campaign #Cancer #Oncology #CancerCare #EarlyDetection #PrecisionMedicine #Healthcare #Research

Congratulations to Dr. @Ammar_Asrar and his team at @NYULangone on their @AnnalsofSurgery paper on the impact of transitional circulating tumor cells (trCTCs) in predicting pancreatic cancer outcomes. Using Rarecells’ ISET® technology, the CLUSTER trial has shown that preoperatively, higher trCTC counts are associated with increased risk of systemic recurrence, while postoperative trCTCs reflect minimal residual disease, supporting more personalized treatment decisions. Read the paper: journals.lww.com/annalsofsurger… #CTCs #Oncology #CancerResearch

Rarecells CEO Patrizia Paterlini, MD, Ph.D. was featured among the health leaders contributing insights during the year, a great example of how ecosystem collaboration accelerates meaningful change. Congratulations to @martingcurley1 and the Digital Health Ecosystem at the Innovation Value Institute, @MaynoothUni for a truly impactful 2025! At Rarecells, we’re excited to see this continued momentum shaping the future of healthcare and proud to be part of a global community driving innovation forward. linkedin.com/feed/update/ur…

Thank you to @SalutEuropa and Oncolife for featuring @Rarecells CEO Patrizia Paterlini, MD, Ph.D. in a recent video interview. Rarecells appreciates the opportunity to share this perspective and to contribute to an important discussion on the future of preventive and #PrecisionMedicine. Read the translated article here: rarecells.com/oncolife-highl… Watch the conversation here: [in Italian] youtube.com/live/wGRapqQDQ…

Rarecells is on the ground in San Francisco for #JPM26! We are meeting with partners throughout Demy-Colton & @Informa’s #BiotechShowcase and spending the week in one-on-one conversations with innovators pushing the boundaries of #LiquidBiopsy and #EarlyCancerDetection. If you’re attending JPM week and would like to connect, reach out to contact@rarecells.com. Looking forward to great discussions across San Francisco this week.

Rarecells will be at the 44th Annual J.P.Morgan Healthcare Conference Week in San Francisco next week! Rarecells will be attending Demy-Colton & @Informa’s #BiotechShowcase for one-on-one partnering meetings during #JPM26. We’re eager to connect with leaders driving progress in #LiquidBiopsy and #EarlyCancerDetection, and to share how Rarecells unlocks the next frontier of liquid biopsy sensitivity. Contact us at contact@rarecells.com if you’re interested in connecting!

As we close out the year, Rarecells extends our warmest wishes to our partners, colleagues, and community. Thank you for your continued trust and support as we work to advance innovative solutions in liquid biopsy and early cancer detection. May this season bring you peace, joy, and renewed inspiration. We look forward to making an even greater impact together in the coming year.

@NYTimes’s recent article on #EarlyCancerDetection highlights the significant progress made in #LiquidBiopsy development, as well as the significant promise these technologies hold for improving cancer detection and management. The article also underscores an important opportunity to enhance the sensitivity of liquid biopsies in early-stage cancer. Rarecells’ next-generation ISET® CTC-DNA technology is designed to complement ctDNA-based liquid biopsy approaches by enabling combined analysis of circulating tumor DNA (ctDNA) and tumor DNA derived from circulating tumor cells (CTC-DNA). Read the article here: nytimes.com/2025/12/02/wel… Learn more about the Rarecells clinical study preliminary results here: rarecells.com/clinical-studi…

Rarecells is heading to JPMorgan Healthcare Conference Week in San Francisco next month! We’ll be attending Demy Colton & @Informa’s #BiotechShowcase for one-on-one partnering meetings. We’re looking forward to joining industry leaders, innovators, and partners to discuss the future of #LiquidBiopsy and #EarlyCancerDetection. If you’ll be at #JPM26, we’d love to connect and share how Rarecells is advancing diagnostics that are shaping the next era of cancer care. Reach out to us at contact@rarecells.com if you’d like to connect!

🎉 Congrats to Dr. Ammar Javed and his team at NYU Langone on the new @AnnalsofSurgery publication: “Transitional Subtype of Circulating Tumor Cells in Early Post-Operative Period of 5-Year Survivors Following Resection of PDAC.” Using Rarecells’ proprietary ISET® technology, the study shows that postoperative transitional circulating tumor cells (#trCTCs) are one of the strongest predictors of Long Term Survival in patients treated by resection of #PancreaticCancer. trCTCs are tumor cells found in the blood that are transforming into invasive mesenchymal cells, which play a key role in metastasis. These findings underscore the growing importance of #CTC subtyping and highlight the potential of ISET® for Minimal Residual Disease (MRD) detection and more informed postoperative management in #PancreaticCancer. Read the study here: pubmed.ncbi.nlm.nih.gov/40899903